Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Overview
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in Therapeutics Development
ADRx Inc
Akcea Therapeutics Inc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Autotac Bio Inc
BridgeBio Pharma Inc
BSIM Therapeutics SA
Corino Therapeutics Inc
Covalent Bioscience Inc
Galmed Pharmaceuticals Ltd
Novo Nordisk AS
Proclara Biosciences Inc
Regeneron Pharmaceuticals Inc
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles
acoramidis hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALNTTRSC-04 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Amilo-5MER - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antibody to Inhibit TTR for Familial Transthyretin Amyloidosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
ATC-202 - Drug Profile
Product Description
Mechanism Of Action
doxycycline hyclate - Drug Profile
Product Description
Mechanism Of Action
History of Events
eplontersen sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
inotersen sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclol Antibody for Familial Amyloid Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
NI-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NTLA-2001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
patisiran - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRX-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Transthyretin for Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
tafamidis meglumine - Drug Profile
Product Description
Mechanism Of Action
History of Events
tolcapone - Drug Profile
Product Description
Mechanism Of Action
History of Events
vutrisiran - Drug Profile
Product Description
Mechanism Of Action
History of Events
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Products
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Discontinued Products
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Product Development Milestones
Featured News & Press Releases
Aug 18, 2022: Alnylam to present data from the APOLLO-B phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy at the 18th Intertiol Symposium on amyloidosis
Aug 03, 2022: Alnylam reports positive topline results from APOLLO-B phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy
Jul 22, 2022: Alnylam receives positive CHMP opinion for vutrisiran for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy
Jul 20, 2022: Orsini Specialty Pharmacy selected as limited distribution partner for AMVUTTRA (vutrisiran)
Jun 24, 2022: Intellia and Regeneron present updated interim data from phase 1 Study of CRISPR-based NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis demonstrating that deep serum TTR reductions remained durable after a single dose
Jun 22, 2022: AstraZeneca-Ionis’ eplontersen meets endpoints in Phase III ATTRv-PN trial
Jun 13, 2022: Alnylam announces FDA approval of AMVUTTRA (vutrisiran), an Ri therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Jun 08, 2022: Intellia Therapeutics to present updated interim clinical data from ongoing phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis at the Intertiol Liver Congress 2022
May 23, 2022: Alnylam presents new 18-month results from exploratory cardiac endpoints in HELIOS-A phase 3 study of investigatiol vutrisiran
Apr 04, 2022: Alnylam announces 3-Month extension of review period for New Drug Application for Vutrisiran
Apr 03, 2022: BridgeBio Pharma presents updated rsults from phase 2 open-label extension study of Acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM)
Mar 28, 2022: BridgeBio Pharma to present updated results from phase 2 open-label extension study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Mar 01, 2022: Intellia, Regeneron report positive Phase I transthyretin amyloidosis data
Feb 17, 2022: Intellia Therapeutics announces two upcoming investor events in February 2022
Jan 24, 2022: Eplontersen granted Orphan Drug Desigtion in the US for transthyretin amyloidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by ADRx Inc, 2022
Pipeline by Akcea Therapeutics Inc, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Alnylam Pharmaceuticals Inc, 2022
Pipeline by Autotac Bio Inc, 2022
Pipeline by BridgeBio Pharma Inc, 2022
Pipeline by BSIM Therapeutics SA, 2022
Pipeline by Corino Therapeutics Inc, 2022
Pipeline by Covalent Bioscience Inc, 2022
Pipeline by Galmed Pharmaceuticals Ltd, 2022
Pipeline by Novo Nordisk AS, 2022
Pipeline by Proclara Biosciences Inc, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022